Tag: Abbvie

The estimated annual cost for Vyalev (foscarbidopa-foslevodopa) treatment ranges from approximately $62,023 to a wholesale acquisition cost of $119,000 per patient [1.2.1, 1.2.3]. This guide explores the various factors that influence the final price of this advanced Parkinson's disease therapy.

While the list price for brand-name Humira is in the thousands of dollars, a 2018 report cited an annual cost of around $20,186 for Canadians, though very few pay this amount out of pocket. The real answer to **how much does Humira cost in Canada** depends heavily on provincial drug programs, private insurance, and the shift towards lower-cost biosimilars.

According to AbbVie's financial reports in late 2024, the interleukin-23 inhibitor Skyrizi officially surpassed the TNF-alpha inhibitor Humira in quarterly and annual sales, marking a major market shift. This directly answers the question, is Skyrizi overtaking Humira?, and signals a new era in the treatment of autoimmune conditions.

The list price for a 30-day supply of Vraylar (cariprazine) was reported to be over $1,500 in early 2025, but the amount a patient actually pays for a 30-day prescription of Vraylar varies dramatically based on insurance coverage, pharmacy, and available savings programs. While the cash price is high, most patients do not pay the full retail amount, with many paying significantly less, or even nothing, with the right assistance.

With the annual cost of Vraylar without insurance potentially exceeding $20,000, many patients find themselves searching for strategies to afford this crucial medication. This guide explores practical ways to reduce your out-of-pocket expenses and navigate the complex system of prescription drug pricing, answering the critical question: **how can I make Vraylar affordable?**.

In September 2024, a Class II recall was issued for several lots of Refresh PM lubricant eye ointment by its manufacturer, AbbVie (Allergan), addressing consumer concerns like 'Is there a recall on Refresh PM lubricant eye ointment?'. The recall was prompted by sterility concerns due to compromised tube seals, affecting over 3 million tubes across several countries.

With more than 18 million people in the U.S. affected by major depressive disorder, Viibryd represents a crucial treatment option, but the pharmaceutical manufacturer behind this drug has a complex history. The brand-name version is currently produced by AbbVie Inc., though its origins trace back through a series of corporate acquisitions and licensing agreements.

An estimated 24 million people worldwide live with schizophrenia, yet medication adherence remains a challenge, with a discontinuation rate of 74% within 18 months [1.6.2]. This reality drives the search for better treatments. When asking, **What is AbbVie's new schizophrenia drug?**, the answer involves a promising but ultimately unsuccessful investigational drug named emraclidine and the company's existing portfolio.

As of late 2025, the brand-name Lupron Depot and other leuprolide acetate products remain fully available in the US, manufactured by AbbVie, despite past supply chain disruptions and a discontinued formulation.

Once the world's top-selling drug with peak annual sales exceeding $20 billion, Humira is experiencing a dramatic market shift [1.2.3, 1.5.7]. This article explores what is going on with Humira as its sales decline and a wave of biosimilar competitors enters the scene.